gw420867x has been researched along with lamivudine in 1 studies
| Studies (gw420867x) | Trials (gw420867x) | Recent Studies (post-2010) (gw420867x) | Studies (lamivudine) | Trials (lamivudine) | Recent Studies (post-2010) (lamivudine) |
|---|---|---|---|---|---|
| 17 | 5 | 2 | 7,025 | 1,425 | 2,177 |
| Protein | Taxonomy | gw420867x (IC50) | lamivudine (IC50) |
|---|---|---|---|
| Capsid protein | Hepatitis B virus | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
1 other study(ies) available for gw420867x and lamivudine
| Article | Year |
|---|---|
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |